Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

被引：0
|
作者：
Yuxin Mu
Xuezhi Hao
Puyuan Xing
Xingsheng Hu
Yan Wang
Teng Li
Jinyao Zhang
Ziyi Xu
Junling Li
机构：
[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Non-small-cell lung cancer; Osimertinib; T790M; Resistance mechanism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2427 / 2433
页数：6
相关论文
共 50 条
  • [41] Resistance to chemoimmunotherapy in non-small-cell lung cancer
    Hochmair, Maximilian Johannes
    CANCER DRUG RESISTANCE, 2020, 3 (03) : 445 - 453
  • [42] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [43] CLINICAL STAGING OF PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
    LITTLE, AG
    STITIK, FP
    CHEST, 1990, 97 (06) : 1431 - 1438
  • [44] Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
    Dong, Lijun
    Lei, Dan
    Zhang, Haijun
    ONCOTARGET, 2017, 8 (38) : 64600 - 64606
  • [45] Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
    Zixi Wang
    Yurou Xing
    Bingjie Li
    Xiaoyu Li
    Bin Liu
    Yongsheng Wang
    Molecular Biomedicine, 3
  • [46] Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
    Wang, Zixi
    Xing, Yurou
    Li, Bingjie
    Li, Xiaoyu
    Liu, Bin
    Wang, Yongsheng
    MOLECULAR BIOMEDICINE, 2022, 3 (01):
  • [47] Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer
    Chen, Wu
    Yu, Danlei
    Sun, Shi-Yong
    Li, Feng
    ACTA BIOMATERIALIA, 2021, 129 : 258 - 268
  • [48] Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters
    Xu, Y.
    Zhu, L.
    Ma, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S486 - S486
  • [49] Managing non-small-cell lung cancer with acquired resistance to EGF receptor and ALK inhibitors
    Lee, Siow-Ming
    King, Judy
    LUNG CANCER MANAGEMENT, 2013, 2 (01) : 23 - 26
  • [50] The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers
    Vishwanathan, Karthick
    Dickinson, Paul A.
    Bui, Khanh
    Cassier, Philippe A.
    Greystoke, Alastair
    Lisbon, Eleanor
    Moreno, Victor
    So, Karen
    Thomas, Karen
    Weilert, Doris
    Yap, Timothy A.
    Plummer, Ruth
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (04): : 474 - 484
12345